{{Update |date=January 2014}}

{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443795292
| IUPAC_name = 4-amino-5-fluoro-1-[(2''S'',5''R'')-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
| image = Elvucitabine structure.svg

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 181785-84-2
| ATC_prefix = none
| ATC_suffix =
| PubChem = 469717
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = M09BUF90C0
| NIAID_ChemDB = 060327
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 38700
| ChemSpiderID = 412628

<!--Chemical data-->
| C=9 | H=10 | F=1 | N=3 | O=3
| molecular_weight = 227.19 g/mol
| smiles = c1c(c(nc(=O)n1[C@@H]2C=C[C@@H](O2)CO)N)F
| StdInChI = 1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m1/s1
| StdInChIKey = HSBKFSPNDWWPSL-VDTYLAMSSA-N

}}

'''Elvucitabine''' is an experimental [[nucleoside reverse transcriptase inhibitor]] (NRTI), developed by [[Achillion Pharmaceuticals]], Inc. for the treatment of [[HIV/AIDS|HIV infection]].

Elvucitabine belongs to a class (group) of HIV drugs called nucleoside reverse transcriptase inhibitors (NRTIs).<ref>[http://chemdb.niaid.nih.gov/DrugDevelopmentHIV.aspx]</ref> NRTIs block an HIV enzyme called reverse transcriptase. (An enzyme is a protein that starts or increases the speed of a chemical reaction). By blocking reverse transcriptase, NRTIs prevent HIV from multiplying and can reduce the amount of HIV in the body.

Elvucitabine is similar in chemical structure to the FDA-approved NRTIs [[lamivudine]] (brand name '''Epivir''') and [[emtricitabine]] (brand name '''Emtriva'''). However, ''in vitro'' studies have suggested that elvucitabine may work on certain HIV strains against which other NRTIs, such as lamivudine and emtricitabine, no longer work. (''In vitro'' studies are studies done in test tubes or other laboratory equipment and not on animals or humans).

Studies have also suggested that elvucitabine may be effective against [[hepatitis B virus]] (HBV)<ref>[http://aidsinfo.nih.gov/drugs/385/elvucitabine/0/patient ]</ref>

Currently, it is in [[Phases of clinical research#Phase II|Phase II clinical trials]].<ref>{{cite web |url=http://www.aidsmeds.com/archive/elvucitabine_1592.shtml |publisher=AIDSmeds.com |title=Elvucitabine |accessdate=March 21, 2008 |date=November 5, 2007 |deadurl=yes |archiveurl=https://web.archive.org/web/20080321130935/http://www.aidsmeds.com/archive/elvucitabine_1592.shtml |archivedate=March 21, 2008 |df= }}</ref>

==References==
{{Reflist}}

{{Antiretroviral drug}}

[[Category:Dihydrofurans]]
[[Category:Nucleoside analog reverse transcriptase inhibitors]]
[[Category:Organofluorides]]
[[Category:Pyrimidones]]
[[Category:Experimental drugs]]

{{Antiinfective-drug-stub}}